NASDAQ:RAREUltragenyx Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $68.59 -2.52 (-3.54 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$68.34Now: $68.59▼$72.6750-Day Range$50.71MA: $63.62▼$73.8152-Week Range$31.99Now: $68.59▼$76.00Volume357,800 shsAverage Volume580,261 shsMarket Capitalization$4.09 billionP/E RatioN/ADividend YieldN/ABeta2.22 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $77.09, Ultragenyx Pharmaceutical has a potential upside of 12.4% from its current price of $68.59.Amount of Analyst CoverageUltragenyx Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Previous Next 3.4 Community Rank Outperform VotesUltragenyx Pharmaceutical has received 725 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUltragenyx Pharmaceutical has received 357 “underperform” votes. (Add your “underperform” vote.)Community SentimentUltragenyx Pharmaceutical has received 67.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote “Outperform” if you believe RARE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,182,726.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions99.92% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.44) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 6.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE Previous Symbol CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone415-483-8800Debt Debt-to-Equity Ratio0.06 Current Ratio4.54 Quick Ratio4.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$103.71 million Price / Sales39.45 Cash FlowN/A Price / Cash FlowN/A Book Value$10.21 per share Price / Book6.72Profitability EPS (Most Recent Fiscal Year)($7.36) Net Income$-402,730,000.00 Net Margins-348.78% Return on Equity-60.65% Return on Assets-40.51%Miscellaneous EmployeesN/A Outstanding Shares59,653,000Market Cap$4.09 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:RARE Rates by TradingView Receive RARE News and Ratings via Email Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions How has Ultragenyx Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RARE stock has increased by 51.2% and is now trading at $68.59. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ultragenyx Pharmaceutical. When is Ultragenyx Pharmaceutical's next earnings date? Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Ultragenyx Pharmaceutical. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($1.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.68) by $0.23. The biopharmaceutical company earned $36.31 million during the quarter, compared to analysts' expectations of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The business's revenue was up 99.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.82) earnings per share. View Ultragenyx Pharmaceutical's earnings history. What price target have analysts set for RARE? 13 analysts have issued 12-month target prices for Ultragenyx Pharmaceutical's stock. Their forecasts range from $66.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $77.09 in the next year. This suggests a possible upside of 12.4% from the stock's current price. View analysts' price targets for Ultragenyx Pharmaceutical. What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock? Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock: 1. According to Zacks Investment Research, "Ultragenyx witnessed growth in the demand for Crysvita for both children and adults with X-linked hypophosphatemia in the United States. The drug's performance has been impressive so far. The company is also expanding the label of the drug and filed an sBLA for the same for the treatment of tumor-induced osteomalacia. The company’s NDA for a potential approval of its third therapy, UX007, in fatty acid oxidation disorders is under review with the FDA. Ultragenyx continues to advance two gene-therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency. However, being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital." (4/16/2020) 2. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019) Has Ultragenyx Pharmaceutical been receiving favorable news coverage? Press coverage about RARE stock has trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 0.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutUltragenyx Pharmaceutical. Who are some of Ultragenyx Pharmaceutical's key competitors? Some companies that are related to Ultragenyx Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Merck KGaA (MKGAF), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Beigene (BGNE), Sarepta Therapeutics (SRPT), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Mylan (MYL), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS) and ACADIA Pharmaceuticals (ACAD). View all competitors. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Gilead Sciences (GILD), Exelixis (EXEL), TG Therapeutics (TGTX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH) and Intercept Pharmaceuticals (ICPT). Who are Ultragenyx Pharmaceutical's key executives? Ultragenyx Pharmaceutical's management team includes the following people: Emil D. Kakkis, President, Chief Executive Officer & DirectorWladimir Hogenhuis, Chief Operating OfficerShalini Sharp, Chief Financial Officer & Executive Vice PresidentDennis Karl Huang, Chief Technical Operations Officer & Senior VPEric Crombez, Chief Medical Officer What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Capital Research Global Investors (11.02%), Capital International Investors (10.28%), BlackRock Inc. (7.88%), Federated Hermes Inc. (6.73%), State Street Corp (3.74%) and Alliancebernstein L.P. (2.37%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View institutional ownership trends for Ultragenyx Pharmaceutical. Which institutional investors are selling Ultragenyx Pharmaceutical stock? RARE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, First Trust Advisors LP, BlackRock Inc., Alliancebernstein L.P., Morgan Stanley, Morgan Stanley, Cinctive Capital Management LP, and AXA. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga. View insider buying and selling activity for Ultragenyx Pharmaceutical. Which institutional investors are buying Ultragenyx Pharmaceutical stock? RARE stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Bank of New York Mellon Corp, Capital Research Global Investors, Fred Alger Management LLC, Capital International Investors, Castleark Management LLC, Geode Capital Management LLC, and Rhenman & Partners Asset Management AB. View insider buying and selling activity for Ultragenyx Pharmaceutical. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $68.59. How big of a company is Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical has a market capitalization of $4.09 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis. What is Ultragenyx Pharmaceutical's official website? The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
